ConductScience.org, home

Paper8558199

Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.

Kobayashi T and 24 others. J Clin Oncol, 1996. Cited by 90 papers, by iCite.

Cite this record

ConductScience Library. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. Papers, record 8558199. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8558199

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
PubMed
Journal
J Clin Oncol
PubMed
Year
1996
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
90
iCite
Relative citation ratio, by iCite
2.18
iCite
Revised in PubMed
2017-11-16
PubMed

Authors25

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kobayashi TT
2Miyawaki SS
3Tanimoto MM
4Kuriyama KK
5Murakami HH
6Yoshida MM
7Minami SS
8Minato KK
9Tsubaki KK
10Ohmoto EE
11Oh HH
12Jinnai II
13Sakamaki HH
14Hiraoka AA
15Kanamaru AA
16Takahashi II
17Saito KK
18Naoe TT
19Yamada OO
20Asou NN

Source PubMed

See all 25 authorsDownload CSV of authors

Topics25

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Leukemia, MyeloidMajor topic
Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Chi-Square Distribution
Cytarabine
Daunorubicin
Disease-Free Survival
Female
Follow-Up Studies
Humans
Leucine
Logistic Models
Male
Mercaptopurine
Middle Aged
Multivariate Analysis
Prednisolone
Prospective Studies
Remission Induction
Survival Rate
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 90 citations.

PMIDTitleJournalYearIn PapersSource
38519889CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.BMC Cancer2024https://conductscience.org/library/papers/38519889PubMed
29984744Very Late Relapse of Acute Promyelocytic Leukemia 17 Years after Continuous Remission.Intern Med2018https://conductscience.org/library/papers/29984744PubMed
29860713Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols.Support Care Cancer2018https://conductscience.org/library/papers/29860713PubMed
29043232Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.Blood Res2017https://conductscience.org/library/papers/29043232PubMed
27354720Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.Blood2016https://conductscience.org/library/papers/27354720PubMed
26829896Improving nucleoside analogs via lipid conjugation: Is fatter any better?Crit Rev Oncol Hematol2016https://conductscience.org/library/papers/26829896PubMed
26375984Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis.PLoS One2015https://conductscience.org/library/papers/26375984PubMed
25609058DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.Clin Cancer Res2015https://conductscience.org/library/papers/25609058PubMed
23135354Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.Leukemia2013https://conductscience.org/library/papers/23135354PubMed
22851055Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group.Int J Hematol2012https://conductscience.org/library/papers/22851055PubMed
22639053
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.
Int J Hematol2012https://conductscience.org/library/papers/22639053PubMed
22220252Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia.Mediterr J Hematol Infect Dis2011https://conductscience.org/library/papers/22220252PubMed
21606963Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia.Leukemia2011https://conductscience.org/library/papers/21606963PubMed
21213127Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group.Int J Hematol2011https://conductscience.org/library/papers/21213127PubMed
20697159CD13 is a therapeutic target in human liver cancer stem cells.J Clin Invest2010https://conductscience.org/library/papers/20697159PubMed
20063133Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.Int J Hematol2010https://conductscience.org/library/papers/20063133PubMed
20054669Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study.Int J Hematol2010https://conductscience.org/library/papers/20054669PubMed
20052341
Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
J Korean Med Sci2010https://conductscience.org/library/papers/20052341PubMed
18055342Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).Int J Hematol2007https://conductscience.org/library/papers/18055342PubMed
15902284Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).Leukemia2005https://conductscience.org/library/papers/15902284PubMed

See all 28 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8558199

GET https://conductscience.org/api/papers/v1/8558199/authors?page=2